Sevoflurane Versus Propofol for Laryngeal Mask Airway Placement in Children Undergoing Surgery

June 24, 2026 updated by: Palwasha Sardar, Children's Hospital and Institute of Child Health, Multan

Comparison of Sevoflurane and Propofol for Laryngeal Mask Airway Insertion in Children

The goal of this clinical trial is to compare two commonly used anesthetic medicines, sevoflurane and propofol, for inserting a laryngeal mask airway (LMA) in children undergoing minor elective surgery. A laryngeal mask airway is a device placed in the throat to help children breathe safely during anesthesia.

The main questions this study aims to answer are:

  • Does sevoflurane produce a faster onset of anesthesia than propofol?
  • Is there a difference between sevoflurane and propofol in the time required to achieve jaw relaxation for LMA insertion?
  • Is there a difference between the two medicines in the time required for successful LMA insertion?

The researchers hypothesize that children receiving sevoflurane will have a shorter induction time than those receiving propofol.

A total of 170 children aged 4 to 12 years who are undergoing minor surgical procedures below the umbilicus will participate in the study. Participants will be randomly assigned to receive either intravenous propofol or inhaled sevoflurane for induction of anesthesia.

During the procedure, the anesthesia team will measure the time taken to lose consciousness, the time required to achieve adequate jaw relaxation, and the time needed for successful insertion of the laryngeal mask airway. These measurements will help determine which anesthetic agent provides better conditions for LMA insertion in children.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

170

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab Province
      • Multan, Punjab Province, Pakistan, 60000
        • Children's Hospital and Institute of Child Health Multan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • ASA physical status 1 and 2
  • Undergoing elective minor surgical procedures below umbilicus
  • Procedure lasting less than 60 min

Exclusion Criteria:

  • Recent respiratory tract infection
  • Bronchial asthma
  • Family history of malignant hyperthermia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Propofol Group
Children in this group will receive intravenous propofol as the induction agent for general anesthesia prior to laryngeal mask airway (LMA) insertion.
Drug: propofol
Intravenous propofol 3 mg/kg bolus will be administered for induction of general anesthesia before LMA insertion in pediatric patients.
Experimental: Sevoflurane Group
hildren in this group will receive inhalational sevoflurane for induction of general anesthesia prior to laryngeal mask airway (LMA) insertion.
Drug: Sevoflurane
Sevoflurane 7% will be delivered via inhalation in a nitrous oxide/oxygen mixture (2:1) for induction of general anesthesia prior to LMA insertion in pediatric patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to Induction of Anesthesia
Time Frame: From administration of the induction agent until loss of consciousness, assessed for up to 5 minutes after induction.
Time (in seconds) measured from administration of the induction agent (propofol or sevoflurane) to loss of consciousness, defined as loss of verbal response and loss of eyelash reflex in pediatric patients undergoing elective surgery for laryngeal mask airway insertion.
From administration of the induction agent until loss of consciousness, assessed for up to 5 minutes after induction.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to Jaw Relaxation
Time Frame: From administration of the induction agent until achievement of adequate jaw relaxation (mouth opening >4 cm), assessed for up to 5 minutes after induction.
Time (in seconds) measured from administration of induction agent to adequate jaw relaxation, defined as sufficient mouth opening (>4 cm) allowing insertion of laryngeal mask airway.
From administration of the induction agent until achievement of adequate jaw relaxation (mouth opening >4 cm), assessed for up to 5 minutes after induction.
Time to Laryngeal Mask Airway (LMA) Insertion
Time Frame: From administration of the induction agent until successful laryngeal mask airway insertion, assessed for up to 5 minutes after induction.
Time (in seconds) measured from administration of induction agent to successful insertion of laryngeal mask airway using standard technique.
From administration of the induction agent until successful laryngeal mask airway insertion, assessed for up to 5 minutes after induction.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Children's Hospital and Institute of Child Health, Multan

Investigators

  • Study Chair: Syed S Abbas, FCPS, Children's Hospital and Institute of Child Health, Multan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2025

Primary Completion (Actual)

November 30, 2025

Study Completion (Actual)

November 30, 2025

Study Registration Dates

First Submitted

June 17, 2026

First Submitted That Met QC Criteria

June 24, 2026

First Posted (Actual)

June 29, 2026

Study Record Updates

Last Update Posted (Actual)

June 29, 2026

Last Update Submitted That Met QC Criteria

June 24, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • U1111-1342-4662

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on General Anaesthesia

Clinical Trials on propofol

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe